Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease.

Bastian D, Wu Y, Betts BC, Yu XZ.

Front Immunol. 2019 May 8;10:988. doi: 10.3389/fimmu.2019.00988. eCollection 2019. Review.

2.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM.

J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0.

3.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

4.

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.

Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS.

Clin Cancer Res. 2018 Dec 15;24(24):6236-6247. doi: 10.1158/1078-0432.CCR-18-1100. Epub 2018 Aug 21.

PMID:
30131384
5.

Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

MacDonald KPA, Betts BC, Couriel D.

Biol Blood Marrow Transplant. 2018 Mar;24(3S):S7-S14. doi: 10.1016/j.bbmt.2017.12.788. Review. No abstract available.

6.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1582-1587. doi: 10.1073/pnas.1712452115. Epub 2018 Jan 30.

7.

Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.

Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J.

Br J Haematol. 2018 Mar;180(6):854-862. doi: 10.1111/bjh.15105. Epub 2018 Jan 18.

PMID:
29345306
8.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):400-405. doi: 10.1016/j.bbmt.2017.09.022. Epub 2017 Oct 13.

9.

Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

MacDonald KPA, Betts BC, Couriel D.

Biol Blood Marrow Transplant. 2018 Jan;24(1):19-26. doi: 10.1016/j.bbmt.2017.10.006. Epub 2017 Oct 12. Review. No abstract available.

10.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C.

Haematologica. 2017 May;102(5):948-957. doi: 10.3324/haematol.2016.153072. Epub 2017 Jan 19.

11.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

12.

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Curran SA, Shyer JA, St Angelo ET, Talbot LR, Sharma S, Chung DJ, Heller G, Hsu KC, Betts BC, Young JW.

Cancer Immunol Res. 2017 Jan;5(1):52-60. doi: 10.1158/2326-6066.CIR-16-0233. Epub 2016 Dec 6.

13.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588. Epub 2015 Apr 3.

14.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1074-82. doi: 10.1016/j.bbmt.2015.03.014. Epub 2015 Mar 21.

15.

Tolerance associated gene expression following allogeneic hematopoietic cell transplantation.

Pidala J, Bloom GC, Eschrich S, Sarwal M, Enkemann S, Betts BC, Beato F, Yoder S, Anasetti C.

PLoS One. 2015 Mar 16;10(3):e0117001. doi: 10.1371/journal.pone.0117001. eCollection 2015.

16.

CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J.

J Leukoc Biol. 2015 Apr;97(4):807-19. doi: 10.1189/jlb.5A1114-532RR. Epub 2015 Feb 6.

17.

STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.

Betts BC, Veerapathran A, Pidala J, Yu XZ, Anasetti C.

J Leukoc Biol. 2014 Feb;95(2):205-13. doi: 10.1189/jlb.0313154. Epub 2013 Sep 25.

18.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C.

Haematologica. 2012 Dec;97(12):1882-9. doi: 10.3324/haematol.2012.067140. Epub 2012 Jun 11.

19.

Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.

Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, Fink MJ, St Angelo ET, Mehrara B, Heller G, Münz C, Altan-Bonnet G, Young JW.

Blood. 2012 May 31;119(22):5182-90. doi: 10.1182/blood-2011-09-382200. Epub 2012 Apr 17.

20.

Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

Betts BC, St Angelo ET, Kennedy M, Young JW.

Blood. 2011 Nov 10;118(19):5340-3. doi: 10.1182/blood-2011-06-363390. Epub 2011 Sep 22.

21.

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.

Betts BC, Abdel-Wahab O, Curran SA, St Angelo ET, Koppikar P, Heller G, Levine RL, Young JW.

Blood. 2011 Nov 10;118(19):5330-9. doi: 10.1182/blood-2011-06-363408. Epub 2011 Sep 13.

22.

Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary?

Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1562-8. doi: 10.1016/j.bbmt.2011.04.004. Epub 2011 Apr 20.

23.

Tregs served sunny-side up.

Betts BC, Young JW.

Blood. 2010 Dec 2;116(23):4736-7. doi: 10.1182/blood-2010-09-307546. No abstract available.

Supplemental Content

Loading ...
Support Center